Tandem autologous-allogeneic stem cell transplantation as a feasible and effective procedure in high-risk lymphoma patients

Crocchiolo, Roberto; Castagna, Luca; Garciaz, Sylvain; Fürst, Sabine; Cheikh, Jean El; Sarina, Barbara; Bramanti, Stéfania; Granata, Angela; Vai, Andrea; Harbi, Samia; Morabito, Lucio; Mohty, Bilal; Giordano, Laura; Devillier, Raynier; Coso, Diane; Balzarotti, Monica; Chabannon, Christian; Carlo‐Stella, Carmelo; Santoro, Armando; Bouabdallah, Réda; Blaise, Didier

doi:10.3324/haematol.2015.129452

Cited by 9 publications

(6 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although high-dose cyclophosphamide followed by GCSF was the most commonly used chemotherapy/cytokine mobilization regimens [ 19 , 27 – 29 ], cyclophosphamide is one of the agents in many conventional chemotherapy regimens for lymphoma. However, PD patients might be resistant to cyclophosphamide.…”

Section: Discussionmentioning

confidence: 99%

“…One potential clinical option for those patients that demonstrate to be refractory to high-dose etoposide is the possibility to receive allogeneic transplantation (allo-SCT) or a tandem transplantation procedure autologous stem cell transplantation as debulking therapy followed by allogeneic transplantation. Crocchiolo [ 29 ] et al data showed that after allogeneic stem cell transplantation, the 3-year OS, PFS, non-relapse mortality, and relapse/progression were 68 (95% CI 59–77), 61 (95% CI 52–70), 17 (95% CI 10–25), and 22% (95% CI 14–30). Nishitha M [ 30 ] et al data showed that 5-year OS rates between APBSCT and allo-SCT were 59% (95% CI, 51–66%) vs 52% (95% CI, 40–63%), P = 0.5, respectively.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

High-dose etoposide could discriminate the benefit from autologous peripheral blood stem cell transplantation in the patients with refractory diffuse large B cell lymphoma

et al. 2019

View full text Add to dashboard Cite

To evaluate the strategy of using high-dose etoposide mobilization followed by autologous peripheral blood stem cell transplantation (APBSCT) in patients with diffuse large B cell lymphoma (DLBCL) refractory to rituximab-based chemotherapy. Forty patients with refractory DLBCL were treated with high-dose etoposide for stem cell mobilization. All patients were in progressive disease (PD) prior to mobilization and underwent high-dose chemotherapy followed by APBSCT. Successful PBSC mobilization was achieved in all patients. Twenty-three patients (57.5%) showed a clinical response to high-dose etoposide. After APBSCT, 17 patients (42.5%) achieved CR. The 2-year progression-free (PFS) and overall survival (OS) rate were higher in patients responding to high-dose etoposide (64.1% and 77.7%) compared to those without response (11.8% and 11.8%; P < 0.001 for both). The response to high-dose etoposide mobilization therapy was an independent prognostic factor for CR achievement, PFS and OS after APBSCT. High-dose etoposide mobilization chemotherapy followed by APBSCT could rescue a proportion of patients with refractory DLBCL who responded to etoposide mobilization regimen.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

High-dose etoposide could discriminate the benefit from autologous peripheral blood stem cell transplantation in the patients with refractory diffuse large B cell lymphoma

et al. 2019

View full text Add to dashboard Cite

show abstract

“…They had a history of disease relapse after several chemotherapeutic lines or after a previous autologous or allogeneic HSCT; or they were refractory to conventional salvage chemotherapy and thus, were candidates for an auto-allo strategy consisting of autologous HSCT followed by haplo-HSCT. 17 Main patients’ and transplant characteristics are shown in Table 1 . Patients with prior IFI were excluded.…”

Section: Methodsmentioning

confidence: 99%

Comparison of Three Distinct Prophylactic Agents Against Invasive Fungal Infections in Patients Undergoing Haplo-Identical Hematopoietic Stem Cell Transplantation and Post-Transplant Cyclophosphamide

El-Cheikh

Crocchiolo

Vai

et al. 2015

Mediterr J Hematol Infect Dis

View full text Add to dashboard Cite

Over the past decade, invasive fungal infections (IFIs) have remained an important problem in patients undergoing allogeneic haematopoietic stem cell transplantation (Allo-HSCT). The optimal approach for prophylactic antifungal therapy has yet to bedetermined.We conducted a retrospective analysis, comparing the safety and efficacy of micafungin 50mg/day vs. fluconazole 400mg/day vs. itraconazole 200mg/day as prophylaxis for adult patients with various haematological diseases receiving haploidentical hematopoietic stem cell transplantation (haplo-HSCT) followed by high-dose cyclophosphamide (PT-Cy).Overall, 99 patients were identified: 30 patients received micafungin, 50 and 19 patients received itraconazole and fluconazole, respectively. After a median follow-up of 12 months (range: 1–51), proven or probable IFIs were reported in 3 patients (10%) in the micafungin, 5 patients in the itraconazole (10%) and 2 patients (11%) in the fluconazole group (p=0.998). Fewer patients in the micafungin group had invasive aspergillosis (1 [3%] vs. 3 [6%] in the itraconazole vs. 2 [11%] in the fluconazole group, p=0.589). Four patients (13%) in the micafungin group vs 13 (26%) patients in the itraconazole group and 10 (53%) patients in the fluconazole received empirical antifungal therapy (P = 0.19).No serious adverse events related to treatment were reported by patients, and there was no treatment discontinuation because of drug-related adverse events in both groups.The present analysis shows that micafungin did better than fluconazole in preventing invasive aspergillosis after transplant in these high-risk hematological diseases, as expected. In addition, micafungin was more effective than itraconazole in preventing all IFI episodes when also considering possible fungal infections. Future prospective studies would shed light on this issue, concerning this increasingly used transplant platform.

show abstract

“…Crocchiolo et al 20 reported a 68% 5-year PFS in 34 patients with high-risk relapsed NHL who underwent tandem autoHCT followed by alloHCT at 2 centers in Italy. In a larger retrospective analysis of 111 patients with high-risk lymphoma who underwent tandem autoHCT followed by alloHCT, Crocchiolo et al 21 again proved the safety and efficacy of this approach, reporting that the 39 patients with aggressive NHL and chemosensitive disease obtained a 3-year PFS of 65%. Chen et al 22 reported the largest prospective series to date of tandem autoHCT followed by alloHCT in high-risk lymphoma.…”

Section: Tandem Autologous and Allogeneicmentioning

confidence: 98%

Hematopoietic Progenitor Cell Transplantation in Children, Adolescents, and Young Adults With Relapsed Mature B-Cell NHL

Gardenswartz¹,

Cairo²

2020

Journal of the National Comprehensive Cancer Network

View full text Add to dashboard Cite

Although children, adolescents, and young adults with newly diagnosed B-cell non-Hodgkin’s lymphoma enjoy excellent overall survival with current chemoimmunotherapy, those with relapsed and/or refractory disease have a dismal prognosis. Although most clinicians would agree that hematopoietic progenitor cell transplantation after reinduction therapy is frontline therapy for these patients, there is no consensus as to what type of hematopoietic progenitor cell transplantation promises the best event-free and overall survival. This review outlines the disparate types of stem cell therapy that have been used in this difficult-to-treat population as well as the role of maintenance and CAR T-cell therapy in conjunction with stem cell therapy.

show abstract

Tandem autologous-allogeneic stem cell transplantation as a feasible and effective procedure in high-risk lymphoma patients

Cited by 9 publications

References 16 publications

High-dose etoposide could discriminate the benefit from autologous peripheral blood stem cell transplantation in the patients with refractory diffuse large B cell lymphoma

High-dose etoposide could discriminate the benefit from autologous peripheral blood stem cell transplantation in the patients with refractory diffuse large B cell lymphoma

Comparison of Three Distinct Prophylactic Agents Against Invasive Fungal Infections in Patients Undergoing Haplo-Identical Hematopoietic Stem Cell Transplantation and Post-Transplant Cyclophosphamide

Hematopoietic Progenitor Cell Transplantation in Children, Adolescents, and Young Adults With Relapsed Mature B-Cell NHL

Contact Info

Product

Resources

About